This study is looking at people with hepatocellular carcinoma (HCC), a type of liver cancer, who are receiving Y90 radioembolization treatment. Researchers want to see if they can use "liquid biopsies" (blood tests that look for cancer cells or DNA in your blood) to predict how well you will respond to Y90 treatment. They will collect blood samples at different times to look for circulating tumor cells (CTCs) and cell-free DNA (cf-DNA) from your cancer. This study aims to understand if these blood tests, along with imaging, can help predict treatment success. You may be able to join if you are at least 18 years old, have HCC, and your doctors have approved you for Y90 treatment.

Study design

This is an observational study with a planned enrollment of 12 participants. It is not a randomized trial, meaning participants are not assigned to different treatment groups.

What's involved

You would have blood samples taken at the start of the study, and then again 1 month, 3 months, and 6 months after your Y90 treatment. You would also have CTA imaging scans at the start, 3 months, and 6 months after treatment.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for at least 6 months after their Y90 treatment, with assessments at 1, 3, and 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.